[LDL cholesterol lowering therapy: no target value but personalised treatment]

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Pharmacotherapy

Background:

• Previous recommendations advised LDL cholesterol lowering therapy based on event risk, not arbitrary targets.
• Efficacy of ezetimibe in preventing cardiovascular events required documentation before widespread use.

Purpose of the Study:

• To evaluate the efficacy and cost-effectiveness of combination therapy (simvastatin plus ezetimibe) compared to simvastatin alone.
• To inform updated guidelines on lipid-lowering therapies for cardiovascular event prevention.

Main Methods:

• A large, randomized trial (IMPROVE-IT) involving patients treated for 7 years.
• Comparison of simvastatin monotherapy versus simvastatin plus ezetimibe combination therapy.

Main Results:

• A modest benefit was observed with simvastatin plus ezetimibe over simvastatin alone after 7 years.
• The combination therapy demonstrated similar efficacy to high-dose statin therapy but at a higher cost.

Conclusions:

• Combination therapy (simvastatin plus ezetimibe) offers a modest benefit but is more expensive than statins alone.
• Recommended first-line therapy includes aspirin and moderate-dose statins, followed by ACE inhibitors.
• High-dose statins are for high-risk patients; simvastatin/ezetimibe is reserved for high-risk patients intolerant to high-dose statins.